

An approach for establishing OncoPrint Focus Assay performance

Introduction

Cancer is understood to be a disease of the genome with different hallmarks that include genome instability and an accumulation of somatic mutations. While cancers are characterized by numerous genomic aberrations, some of these somatic mutations, known as driver mutations, induce growth and impaired differentiation leading to cancer development. The identification of these driver mutations in a tumor enables the development of targeted therapies directed against the specific molecular alterations driving the tumor.

Recent advances in genome sciences, including next-generation sequencing (NGS), have led to the identification of hundreds of somatically altered genes through the analysis of tens of thousands of cancer samples from individual investigators and large consortia, such as The Cancer Genome Atlas (TCGA). These technological advances are also changing routine molecular pathology research from single gene-based tests (e.g., Sanger sequencing to assess *EGFR* mutations in lung tumor samples) to multiplexed NGS assays.

Next-generation sequencing solutions that can assess all classes of relevant targets, including point mutations, short insertions or deletions (indels), copy number variants (CNVs), and gene fusions from formalin-fixed, paraffin-embedded (FFPE) tissues or fine-needle aspirates may help advance cancer research toward a future in which precision medicine approaches for all cancer types are rapid, inexpensive, and scalable. To enable this vision, technical solutions should be coupled with dynamic, scalable, and analytical approaches capable of prioritizing future treatment options.

The Ion Torrent™ OncoPrint™ Focus Assay* is a multibiomarker NGS assay that enables the detection of variants in 52 key solid tumor genes. These genes are well characterized in the published literature and associated with oncology drugs that are FDA approved, part of National Comprehensive Cancer Network (NCCN) guidelines, or in clinical trials. The assay allows concurrent analysis of DNA and RNA to simultaneously detect multiple types of variants, including hotspots, single nucleotide variants (SNVs), indels, CNVs, and gene fusions, in a single workflow. The OncoPrint Focus Assay is based on Ion AmpliSeq™ technology and is designed for use with the Ion PGM™ System, but is also compatible with other Ion Torrent™ sequencing platforms.

Here we describe a study to determine the performance of the OncoPrint Focus Assay in detecting known variants present in commercially available reference and FFPE tissue materials. The study was performed in a laboratory certified by the Clinical Laboratory Improvement Amendments (CLIA) program and accredited by the College of American Pathologists (CAP). The study design was informed by the New York State NGS guidelines for somatic genetic variant detection.

* For Research Use Only. Not for use in diagnostic procedures.

Materials and methods

Gene targets

The biomarkers included in the OncoPrint Focus Assay were selected based on information in the OncoPrint™ Knowledgebase, one of the world's largest collections of curated oncology data [1]. The 52 genes queried by the assay fall into the categories shown in Figure 1.

Samples

DNA samples, cell lines, and FFPE sections were used in this study.

The following molecular standards were used to assess DNA performance:

- Thermo Scientific™ Acrometrix™ Oncology Hotspot Control (Thermo Fisher Scientific, Cat. No. 969056) is a mixture of >500 Catalogue of Somatic Mutations in Cancer (COSMIC) mutations (SNVs, multinucleotide variants (MNVs), insertions, and deletions) across 53 genes that are confirmed by Sanger sequencing. Of these mutations, 69 annotated variants are detectable by the OncoPrint Focus Assay and were included in the performance analysis.
- The Quantitative Multiplex Reference Standard (Horizon Discovery, Cat. No. HD200) is an FFPE section from which DNA was extracted using standard procedures. DNA from the Quantitative Multiplex Reference Standard bears 11 mutations (SNVs and deletions) across cancer driver genes (*BRAF*, *KIT*, *EGFR*, *KRAS*, *NRAS*, and *PIK3CA*) that are confirmed by digital PCR. Of these mutations, 8 are above the limit of detection (LOD) for the OncoPrint Focus Assay as determined in this study. Allele frequency ranged from 1% to 24.5%.

The following samples were used as processing controls:

- For DNA processing, the negative control was Human Genomic DNA: Male (Promega, Cat. No. G1471). As a positive control, an equal mixture of DNA extracted from the following cell lines from ATCC was used: H1975 (*EGFR* mutation), H1650 (*EGFR* mutation), HCT116 (*KRAS* mutation), and A375 (*BRAF* mutation).
- For RNA processing, the negative control was Invitrogen™ Human Lung Total RNA (Thermo Fisher Scientific, Cat. No. AM7968). As a positive control, RNA was extracted from HCC78 (*SLC34A2-ROS* fusion) and H2228 (*EML4-ALK* fusion) cell lines that were obtained from ATCC.

Hotspot genes		Copy number variants	Fusion drivers
35 genes		19 genes	23 genes
DNA			RNA
<i>AKT1</i>	<i>JAK1</i>	<i>ALK</i>	<i>ABL1</i>
<i>ALK</i>	<i>JAK2</i>	<i>AR</i>	<i>ALK</i>
<i>AR</i>	<i>JAK3</i>	<i>BRAF</i>	<i>AKT3</i>
<i>BRAF</i>	<i>KIT</i>	<i>CCND1</i>	<i>AXL</i>
<i>CDK4</i>	<i>KRAS</i>	<i>CDK4</i>	<i>BRAF</i>
<i>CTNNB1</i>	<i>MAP2K1</i>	<i>CDK6</i>	<i>EGFR</i>
<i>DDR2</i>	<i>MAP2K2</i>	<i>EGFR</i>	<i>ERBB2</i>
<i>EGFR</i>	<i>MET</i>	<i>ERBB2</i>	<i>ERG</i>
<i>ERBB2</i>	<i>MTOR</i>	<i>FGFR1</i>	<i>ETV1</i>
<i>ERBB3</i>	<i>NRAS</i>	<i>FGFR2</i>	<i>ETV4</i>
<i>ERBB4</i>	<i>PDGFRA</i>	<i>FGFR3</i>	<i>ETV5</i>
<i>ESR1</i>	<i>PIK3CA</i>	<i>FGFR4</i>	<i>FGFR1</i>
<i>FGFR2</i>	<i>RAF1</i>	<i>KIT</i>	<i>FGFR2</i>
<i>FGFR3</i>	<i>RET</i>	<i>KRAS</i>	<i>FGFR3</i>
<i>GNA11</i>	<i>ROS1</i>	<i>MET</i>	<i>MET</i>
<i>GNAQ</i>	<i>SMO</i>	<i>MYC</i>	<i>NTRK1</i>
<i>HRAS</i>		<i>MYCN</i>	<i>NTRK2</i>
<i>IDH1</i>		<i>PDGFRA</i>	<i>NTRK3</i>
<i>IDH2</i>		<i>PIK3CA</i>	<i>PDGFRA</i>
			<i>PPARG</i>
			<i>RAF1</i>
			<i>RET</i>
			<i>ROS1</i>

Figure 1. List of genes included in the OncoPrint Focus Assay.

The following were used as test samples:

- Three cell lines were obtained from ATCC and used to study analytical sensitivity and establish the LOD for SNVs. The cell lines were H647 (*KRAS* p.G13D), HCT116 (*PIK3CA* p.H1047R and *KRAS* p.G13D), and *SKMEL1* (*BRAF* p.V600E).
- One cell line, HCC4006 with an *EGFR* exon 19 deletion (*EGFR* p.L747_A750delinsP), was obtained from ATCC and used to establish the LOD for indels.
- Two cell lines were obtained from ATCC and used to study analytical sensitivity and establish the LOD for CNVs. The cell lines were H1993 (*MET* and *CDK6* amplification) and H647 (*MYC* amplification).
- A total of 56 FFPE samples were purchased that consisted of 49 solid tumor research samples from Asterand Bioscience and 7 cell lines from ATCC (Table 1). One slide bearing a 7 μm-thick section was obtained per sample. The average tumor cellularity was 65% (range 10–100%) and the average tumor area was 137 mm² (range 5–430 mm²).

Table 1. FFPE test samples.

Tumor type	Number of samples
Brain	4
Breast	5
Cervix	1
Colon	10
Esophagus	1
Lung	13
Melanoma	2
Pancreas	4
Prostate	5
Stomach	2
Uterus	2
Cell lines (H1993, H2228, H647, HCC4006, HCT116, RKO, SKMEL-1)	7
Total	56

Sample processing

Nucleic acid isolation from cell lines and FFPE samples was performed with the Invitrogen™ RecoverAll™ Multi-Sample RNA/DNA Isolation Workflow (Thermo Fisher Scientific, Cat. No. A26135). Extracted RNA and DNA were quantified using the Invitrogen™ Qubit™ 3 Fluorometer (Thermo Fisher Scientific, Cat. No. Q33216). The Invitrogen™ SuperScript™ VILO™ cDNA Synthesis Kit (Thermo Fisher Scientific, Cat. No. 11754050) was used for reverse transcription.

Libraries were prepared from 10 ng DNA and 10 ng RNA with OncoPrint Focus Assay (Thermo Fisher Scientific, Cat. No. A28548) reagents on the Ion OneTouch™ 2 and Ion OneTouch™ ES Systems. The Ion PGM™ Select Library Kit and Ion OneTouch™ Select Template Kit were used. Six samples were run on the Ion 318™ Select Chip using the workflow described in the user guide, with each sample containing 80% DNA and 20% RNA, for a total of 12 barcodes. Sequencing was performed using the Ion PGM™ Select Sequencing Kit and Ion 318™ Select Chip Kit on the Ion PGM System.

Data analysis

Data analysis was performed using Torrent Suite™ Server (ver. 5.0) and Ion Reporter™ Server (ver. 5.0), which includes the OncoPrint™ Variant Annotation Tool (ver. 2.2). All variant types were included to assess correlation for precision and reproducibility.

Performance was computed using the following formulas:

$$\text{Positive predictive value (PPV)} = (\text{CD})/(\text{CD} + \text{FD})$$

$$\text{Negative predictive value (NPV)} = (\text{CN})/(\text{CN} + \text{FN})$$

$$\text{Accuracy} = (\text{CD} + \text{CN})/(\text{CD} + \text{CN} + \text{FN} + \text{FD})$$

$$\text{Sensitivity} = (\text{CD})/(\text{CD} + \text{FN})$$

$$\text{Specificity} = (\text{CN})/(\text{CN} + \text{FD})$$

(CD = confirmed detection, CN = confirmed nondetection, FD = false detection, FN = false non-detection)

Results

DNA sequencing performance

Five replicates of the Acrometrix Oncology Hotspot Control were sequenced on a single Ion 318 chip to assess detection of 69 annotated variants. A variant was called as detected if it was within the expected allele frequency range (either 5–15% or 15–35%) based on the manufacturer's characterization. Table 2 shows the concordance for each replicate run compared to the 69 variants used in the analysis.

Table 2. Concordance of variants in the Acrometrix Oncology Hotspot Control with the expected allele frequency range.

Run	Number detected within allele frequency range	Number not detected within allele frequency range	Concordance
1	69	0	100%
2	68	1	99%
3	68	1	99%
4	69	0	100%
5	68	1	99%

The average concordance was 99%. The 3 variants not in range were all detected and only slightly below the 5% minimum allele frequency reported by the manufacturer.

For the 8 mutations assessed in the Quantitative MultiPlex Reference Standard, the expected vs. observed allele frequency is shown in Figure 2. The correlation coefficient was 0.99.




Figure 2. Expected vs. observed allele frequency in the Quantitative MultiPlex Reference Standard.

The metrics for depth and uniformity of coverage were established across all target areas using 56 FFPE samples. The thresholds and observed ranges are shown in Table 3. Minimum and maximum metrics are based on confirmed detected variants in FFPE samples. The thresholds are based on analytical sensitivity and LOD analysis. The minimum number of variant reads for SNVs and indels was 250.

Table 3. DNA sequencing metrics observed across 56 FFPE samples.

Metric	Threshold	Minimum observed*	Maximum observed*
Tumor reads	NA	3M	4.8M
Tumor percent	0%	10%	100%
Mean depth	850	849	4,234
Uniformity of coverage	75%	74%	100%
Mutation reads	250	143	8,141
Mutation allele frequency	5%	6%	100%
Raw copy number	4.5	3.9	46.4

* Variants observed below threshold are not included in the performance analysis.

To maximize representation of the complete OncoPrint Focus Assay workflow from extraction to sequencing, FFPE samples were used to evaluate accuracy, sensitivity, and specificity. Fifty-six FFPE samples (Table 1, methods section) were used in this assessment. The detected variants for each sample were confirmed by either pre-characterization (i.e., known cell line or characterization by commercial vendor) or testing using an orthogonal method. Confirmation of variants was conducted by the following: SNVs and indels by Sanger sequencing and CNVs by fluorescence *in situ* hybridization (FISH). The results are shown in Table 4.

Table 4. DNA sequencing performance analysis.

Number of variants	SNV	Indel	CNV
Confirmed, detection	36	4	11
Confirmed, nondetection	60	12	8
Confirmed, false detection	1	0	0
Confirmed, false nondetection	0	0	0
PPV	97%	100%	100%
NPV	100%	100%	100%
Accuracy	99%	100%	100%
Sensitivity	100%	100%	100%
Specificity	98%	100%	100%

The number of variants detected using NGS with the OncoPrint Focus Assay exceeded those for which there is an orthogonal method available for testing. Additional variants detected by the OncoPrint Focus Assay could not undergo confirmatory testing, as orthogonal tests are not available for some indels and CNVs. No variants detected by orthogonal methods were missed by NGS, hence no testing was required in the confirmed, false nondetection category.

RNA sequencing performance

The thresholds in Table 5 were established based on internal testing and analysis. Threshold metrics are derived from the LOD studies using the H2228 cell line (*EML4-ALK* fusion).

Table 5. RNA sequencing metrics.

Metric	Threshold	Minimum	Maximum
Tumor percent	0%	10%	100%
Total mapped fusion reads	10,000	131,197	198,759
Fusion reads	20	3,857	130,792

All detected variants (Table 6) exceeded the established thresholds in Table 5. Confirmation of variants was conducted by qPCR analysis and FISH in limited cases.

Table 6. RNA sequencing performance analysis.

Number of variants	Fusion
Confirmed, detection	6
Confirmed, nondetection	20
Confirmed, false detection	0
Confirmed, false nondetection	1
PPV	100%
NPV	95%
Accuracy	98%
Sensitivity	86%
Specificity	100%

The fusions or variants that were detected as well as confirmed were *SCL45A3-ETV1*, *TMPRSS2-ERG*, *PTPRZ1-MET*, *SDC-ROS1*, *EGFRvIII*, and *TPM3-NTRK1*. The one false-negative variant (confirmed, false non-detection) was a *GOPC-ROS1* fusion that had been previously detected by NGS and confirmed using qPCR. A possible explanation for not observing this fusion could be tumor heterogeneity, though further testing is needed to determine the root cause.

Limit of detection, CNV

The cell lines H1993 (*MET* and *CDK6* amplification) and H647 (*MYC* amplification) were diluted in order to adjust the copy number or tumor content. The diluted samples were tested with the Oncomine Focus Assay to determine the detection status at various copy number levels. The copy number gains assessed were 4.5 to 25. In order to determine the raw copy number instead of a tumor copy number, the cellularity was set to 100% for each of the dilution levels.

The analytical sensitivity was 100% at all dilutions with a raw copy gain of 4.5 or greater. The percent of tumor content impacts LOD for tumor copy number. A pathology assessment of the test sample for percent tumor is recommended. Figure 3 shows the relationship between the two and provides guidance for assessing the LOD against percentage of tumor content.




Figure 3. Relationship between tumor content, tumor copy number, and LOD.

Limit of detection, SNVs, and indels

The cell lines H647, HCT116, and SKMEL-1 with known SNVs as well as cell line HCC4006 with known indels were diluted to various target allele frequencies (15%, 10%, 7.5%, 5%). The dilution levels were tested with the Oncomine Focus Assay to determine detection status. Two operators performed the study, with operator 1 performing two replicates for each level. The analytical sensitivity was found to be 100% at an LOD of 5% or greater allele frequency.

Limit of detection, fusions

Cell line H2228, with an *EML4-ALK* fusion, was diluted to vary the amount of reads per targeted fusion. The fusion copy number at each dilution level was determined using 8 replicate runs of a single-analyte qPCR assay. The dilution levels were tested with the OncoPrint Focus Assay to determine the detection status at various read levels. The analytical sensitivity and precision were 100% at an LOD of 225 fusion copies (Table 7).

Table 7. Analytical sensitivity of gene fusion detection.

Dilution	Fusion copies (qPCR)	Sensitivity
1	1,474	100%
2	255	100%
3	144	88%
4	96	88%
5	47	88%

Precision and reproducibility

Cell lines with known variants (SNVs, indels, and CNVs; see methods section) were diluted to various target allele frequencies (15%, 10%, 7.5%, 5%), and were tested with the OncoPrint Focus Assay to determine detection status at the different levels. Two operators performed the assay and each operator ran all samples in duplicate.

The correlation coefficient was calculated for the following combinations for all variant types using relevant output (e.g., allele frequency, copy number):

- **Precision (repeatability):** operator 1 – replicate 1 vs. operator 1 – replicate 2
- **Reproducibility:** operator 1 – replicate 1 and operator 1 – replicate 2 vs. operator 2 – replicate 1

As shown in Table 8, the OncoPrint Focus Assay is highly reproducible and precise.

Table 8. Precision and reproducibility of variant detection.

Variant category	Cell line	Variant	Precision (repeatability)	Reproducibility
SNV	H647	<i>KRAS</i> p.G13D	99%	99%
SNV	HCT116	<i>PIK3CA</i> p.H1047R	98%	99%
SNV	HCT116	<i>KRAS</i> p.G13D	97%	99%
SNV	SKMEL-1	<i>BRAF</i> p.V600E	98%	99%
Indel	HCC4006	<i>EGFR</i> exon 19 deletion	98%	99%
CNV	H1993	<i>CDK6</i> amplification	98%	98%
CNV	H1993	<i>MET</i> amplification	99%	99%
CNV	H647	<i>MYC</i> amplification	99%	99%

Summary and conclusion

A summary of results is shown in Table 9. The results indicate that the OncoPrint Focus Assay is a precise, reproducible, sensitive, and accurate NGS assay for the detection of somatic genetic variants.

Reference

1. Hovelson DH, McDaniel AS, Cani AK et al. (2015) Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. *Neoplasia* 17:385–399.

Table 9. Summary of sequencing results using the OncoPrint Focus Assay.

Category	Result
Performance characteristics, Acrometrix Oncology Hotspot Control (69 variants): concordance, 5 runs	99%
Performance characteristics, Acrometrix Oncology Hotspot Control: variant allele frequency correlation coefficient between 5 runs	98%
Performance characteristics, Quantitative Multiplex Reference Standard (8 mutations): expected vs. observed allele frequency, 1 run	99%
Analytical sensitivity (LOD): SNV	100% at $\geq 5\%$ allele frequency
Analytical sensitivity (LOD): indel	100% at $\geq 5\%$ allele frequency
Analytical sensitivity (LOD): CNV	100% at ≥ 4.5 raw copy number
Analytical sensitivity (LOD): RNA fusion	100% at ≥ 255 fusion copies
Precision (within run) and reproducibility (between runs): SNV	98%; 99%
Precision (within run) and reproducibility (between runs): indel	98%; 99%
Precision (within run) and reproducibility (between runs): CNV	99%; 98%
Precision (within run): RNA fusion	100% at ≥ 255 fusion copies
Accuracy and specificity: SNV (above LOD)	99%; 98%
Accuracy and specificity: indel (above LOD)	100%; 100%
Accuracy and specificity: CNV (above LOD)	100%; 100%
Accuracy and specificity: RNA fusion (above LOD)	98%; 100% at ≥ 255 fusion copies

iontorrent

Find out more at thermofisher.com/oncomine

ThermoFisher
SCIENTIFIC

For Research Use Only. Not for use in diagnostic procedures. © 2016 Thermo Fisher Scientific Inc. All rights reserved.
All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. COL02244 0816